Abstrak
Angiogenesis is the generation of new blood vessels from pre-existing blood vessels. The rate of placental blood flow is dependent on placental vascularization and placental angiogenesis. Placental angiogenesis can be classified as branching and non-branching angiogenesis. In normal pregnancy branching angiogenesis occurs predominantly in the first and second trimester, while non branching angiogenesis occurs in the third trimester. Numerous factors influence placental angiogenic activity, such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and placental oxygenation. 1, 2 It is believed that the placenta is central to the etiology of pre-eclampsia. If the uterine blood vessels do not develop adequate vascular transformation, uterine blood flow is then reduced and placental oxygenation falls. This hypoxia induces VEGF secretion. VEGF is a potent endothelial cell (EC) mitogen. VEGF induces migration and proliferation of EC, causing increased vascular permeability. VEGF also promotes EC survival by inhibiting apoptosis. 3, 4 In early pregnancy, VEGF secretion is enhanced by the human chorionic gonadotropin (hCG) hormone. 5 Patients with overt pre-eclampsia have increased maternal serum hCG levels in the third trimester. The placenta is the main source of hCG in patients with pre-eclampsia. It is suggested that hCG secretion may be increased as a consequence of abnormal placentation or placental immaturity. 6 Increased vascular resistance in fetoplacental circulation is characteristic of preeclampsia. 7 As a response, angiogenic activity will be increased and enhance blood flow in placental microcirculation. Does the hCG concentration in the placenta induce placental angiogenic activity in preeclampsia? It is suggested that hCG induces angiogenic activity via enhances VEGF secretion.
METHODS

Subject
Subjects were selected from Budi Kemuliaan Maternity Hospital. Women with normal pregnancy (10) and with pre-eclampsia (10) were enrolled in this study after they signed an informed consent form. The gestation ranged from 21-40 weeks. Placenta samples were collected immediately after delivery, which was either normal or by cesarean section, and placed in a sterile container filled with RPMI 1640 solution (Flow Laboratories, USA). The sample was then transported to the laboratory within 1 hour.
Upon arrival, the placenta sample was washed with phosphate buffer saline (PBS) and betadine. The connective tissue was discarded. The sample was cultured in conical tubes. 8 Approximately 5 gram of cotyledon was minced finely and teased with PBS, and then centrifuged at 1000 g for 3 minutes. The pellet produced was re-suspended by PBS and then 2 ml Trypsin 0.025% was added. The tube was put into the incubator for 5 minutes, and then 1 ml fetal bovine serum (FBS, Sigma, USA) added. It was recentrifuged at 1000 g for 3 minutes. The pellet was again re-suspended with 3 ml PBS and the remaining red blood cell was lysed using 3 ml hypotonic solution (8.29 g NH 4 Cl, 1.0 g NaHCO 2 and 0.0371 g EDTA in 1 liter H 2 O). The tube again put into incubator for 10 minutes and then re-centrifuged again at 1000 g for 3 minutes. The pellet was re-suspended with 3 ml RPMI 1640, FBS 20%, gentamycin, and Fungizone (Flow Laboratories). Finally, the suspension was incubated at 37  C and 5% CO 2 . After 3 days, the supernatant were collected for -hCG assay.
-hCG assay
The -hCG concentration in the supernatant of the placental culture was measured with the AxSYM Total -hCG kit (Abbot, USA). The supernatant was diluted 1:10, because the concentration of -hCG was predicted to be more than 1000 mIU/ml. The principle of this assay is an antigen-antibody reaction. The -hCG binds to both the enzyme-labeled antibody and the antibody-coated microparticle forming an antibody-antigen-antibody complex. An aliquot of this complex was transferred to the matrix cell and the microparticles bound irreversibly to the fiber of the glass matrix. Addition of 4-methylumbeliferyl phosphate to the matrix cell will lead to production of a fluorescent product. This product was then measured with the Microparticle Enzyme Immunoassay (MEIA) optical assembly.
Angiogenesis assay
Placental angiogenic response was measured based on the migration of endothelial cells toward the placental explants in a three-dimensional collagen matrix culture medium. 9 In this study 10 4 endothelial cell line (Vero) was suspended in 2 ml NCTC (Flow Laboratories), 20% FBS, gentamycin and fungizone. The medium was adjusted by 0.4 ml of 0.1 N NaOH to reach a pH of 7.6 after addition of 2 ml chilled vitrogen 100 (Collagen Corporation, Palo Alto, USA). One ml of the matrix solution was placed to each of the 4 wells in the culture plate (Nunc, Finland). Three or four placental explants measuring 500 m were placed in three wells. The fourth well was used for a control blank.
The culture plate was incubated at 37  C and 5% CO 2 for 96 h and observed at 24 h intervals using inverted phase-contrast microscope. The angiogenic score ranged from 0 to 4. Score 0 = no endothelial cell response, 1 = elongation and some orientation towards explant, 2 = minimal spoke-wheel response, 3 = medium spoke-wheel response and 4 = extreme spoke-wheel formation.
Statistical analysis
Mean -hCG was calculated and the differences between the two groups were analysed using the student's t test. The placental angiogenic score for each placenta was the median response for each placental explant. Differences in placental angiogenic scores between the two groups were analyzed using the Mann-Whitney test. The relationship between -hCG concentration and angiogenic score were analyzed using the Spearman's rank correlation.
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RESULTS
There was no difference in the length of gestation (in weeks) between women with preeclampsia and normal pregnancy (38.8+1.55 weeks versus 37.4+3.80 weeks, p<0.05). The concentration of -hCG was significantly higher in the preeclamptic placenta than in normal pregnancy (3121.5 + 2398.8 mIU/ml versus 653.2 + 643.4 mIU/ml, p<0.001). Placental angiogenic activity was significantly higher in preeclampsia than in normal pregnancy (p<0.05). There was a positive correlation between the concentration of -hCG and the median score of placental angiogenic response both in normal pregnancy (r=0.57) and in preeclampsia (r=0.50).
DISCUSSION
This study showed that placental angiogenic response is significantly higher in women with preeclampsia than the control group. In pre-eclampsia, a reduction of villous oxygen content occurs at term. The placenta adapts to this situation by increasing the highly vascularized terminal villi, which leads to enhanced intra-placental oxygen concentration. 2 There is a general agreement that the placenta remains the main source of hCG in pre-eclampsia. The increased secretion of hCG is a consequence of abnormal placental immaturity. 6 It is suggested that the hCG-mediated effects of VEGF induce increase vascularization or angiogenic activity. 6 In this study, the VEGF was not measured, but a recent study showed that VEGF sera in women with pre-eclampsia is slightly increased.
11 Secretion of hCG also increased in vitro capillary formation and migration of endothelial cells. 12 It is suggested that hCG tends to enhance placental angiogenic activity in preeclampsia.
CONCLUSION
The placental angiogenic response and the concentration of -hCG were significantly higher in women with preeclampsia than the control group. Although the correlation between hCG concentration and angiogenic activity was weak however hCG is still considered one of the many factors which play a role in inducing placental angiogenic activity in pre-eclampsia. 
